On the antibacterial effects of manuka honey: mechanistic insights by Jenkins, Rowena et al.
© 2015 Roberts et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Research and Reports in Biology 2015:6 215–224
Research and Reports in Biology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
215
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/RRB.S75754
On the antibacterial effects of manuka honey: 
mechanistic insights
Aled edward Lloyd 
Roberts*
Helen Louise Brown*
Rowena eleri Jenkins
Department of Biomedical Sciences, 
Cardiff Metropolitan University, 
Cardiff, wales, UK
*These authors contributed equally to 
this work
Correspondence: Rowena eleri Jenkins 
Department of Biomedical Sciences, 
Cardiff Metropolitan University,  
western Avenue, Cardiff CF5 2YB,  
wales, UK 
Tel +44 29 2020 5996 
email rojenkins@cardiffmet.ac.uk
Abstract: Antimicrobial resistance (AMR) is an increasing clinical problem precipitated by the 
inappropriate use of antibiotics in the later parts of the 20th Century. This problem, coupled with 
the lack of novel therapeutics in the development pipeline, means AMR is reaching crisis point, 
with an expected annual death rate of ten million people worldwide by 2050. To reduce, and 
to potentially remedy this problem, many researchers are looking into natural compounds with 
antimicrobial and/or antivirulence activity. Manuka honey is an ancient antimicrobial remedy 
with a good track record against a wide range of nosocomial pathogens that have increased AMR. 
Its inhibitory effects are the result of its constituent components, which add varying degrees 
of antimicrobial efficacy to the overall activity of manuka honey. The antimicrobial efficacy of 
manuka honey and some of its constituent components (such as methylglyoxal and leptosperin) 
are known to bestow some degree of antimicrobial efficacy to manuka honey. Despite growing 
in vitro evidence of its antimicrobial efficacy, the in vivo use of manuka honey (especially in a 
clinical environment) has been unexpectedly slow, partly due to the lack of mechanistic data. The 
mechanism by which manuka honey achieves its inhibitory efficacy has recently been identified 
against Staphylococcus aureus and Pseudomonas aeruginosa, with both of these contrasting 
organisms being inhibited through different mechanisms. Manuka honey inhibits S. aureus by 
interfering with the cell division process, whereas P. aeruginosa cells lyse in its presence due to 
the reduction of a key structural protein. In addition to these inhibitory effects, manuka honey 
is known to reduce virulence, motility, and biofilm formation. With this increasing in vitro 
dataset, we review the components and our mechanistic knowledge of manuka honey and how 
manuka honey could potentially be utilized in the future to impact positively on the treatment 
of microbial, resistant infections.
Keywords: Staphylococcus aureus, Pseudomonas aeruginosa, biofilm, antibiotic resistance
Introduction
The problem of antibiotic resistance
The ability of bacteria to adapt and become resistant to antibiotics has been recognized 
by the scientific community for many decades. Staphylococcus aureus,1 Acinetobacter 
baumannii,2 and Enterococci species3 are just some of the nosocomial pathogens 
with increased antimicrobial resistance (AMR) that cause difficult-to-treat infections 
worldwide. AMR is commonly accrued through genetic changes, which confer a more 
resistant phenotype on the cell, or through the integration of the cell into a biofilm, 
which can lead to a transient increase in tolerance to antibiotics of up to 1,000-fold.4 The 
biofilm phenotype is commonly found in urinary tract infections,5 multi-species chronic 
otitis media,6,7 and Pseudomonas aeruginosa infections in both burns8 and the cystic 
fibrosis lung.9 The prolonged over- and misuse of antibiotics,10 dwindling antibacterial 
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development,11 and lack of funding for novel therapeutic 
research12 has allowed AMR to reach crisis point.
AMR infections are a major health care burden, leading 
to increased morbidity, mortality, and treatment costs.13 
A recent study estimated the total cost of an AMR infec-
tion at between US$70,000 and US$100,000 per person.14 
However it has been suggested that the cost of AMR could 
be much higher as routine operations, which require pro-
phylactic use of antibiotics (eg, cancer therapy and joint/
organ replacements) would also be affected.15 Recently, 
initiatives that are designed to stimulate novel therapeutic 
development, such as the Longitude prize, have been insti-
gated; however, compounds from these initiatives will not 
be available for several years, due to the inherent lag time 
in the development process.
To address the issue of AMR in the short term, researchers 
have generally taken one of two approaches: 1) recombining 
existing antimicrobial formulations to produce novel combi-
nations; or 2) investigating alternative treatment therapies, 
while restricting the use of antimicrobial agents that are still 
currently effective.16 Many of these therapies have shown 
promise, as they provide a broad spectrum of activity, tar-
geting multiple cellular processes and therefore reducing 
the likelihood of AMR arising.17–20 Some of the alternative 
antimicrobial therapies investigated include nanoparticles,21 
bacteriophage “cocktails”,22 and natural substances such as 
honey.23,24
Honey as an antimicrobial
Honey has been used for many centuries as a sweeter, food 
preservative, and therapeutic product.25 It is produced by 
honey bees (Apis mellifera) and is formed by ripening nec-
tar, honeydew, and bee secretions.26 Honey can contain over 
200 compounds,27 being broadly comprised of sugars, amino 
acids, vitamins, minerals, enzymes, flavonoids, phenolic 
acids, and antioxidants.28 The exact composition of honey 
differs depending on the plants foraged by the bees, environ-
mental conditions, and downstream processing.29 In ancient 
times, medical treatises described how different honeys 
should be selected for different ailments,30 and scientific 
evidence is now emerging that also supports the careful selec-
tion of honeys for medical use.30 For example, honeys that are 
darker in color, such as manuka and buckwheat, have higher 
antioxidant activity than lighter honeys.31 Honey is reported 
to have immunomodulatory,32 antidiabetic,33,34 antitumor,35 
antifungal,36 antiviral,37 and antibacterial properties.23,38–40 
A brief summary of the historical and modern medical claims 
for use of honey can be found in Table 1.
There has been a renewed interest in using honey, in par-
ticular manuka honey, to treat bacterial infections, especially 
those with AMR characteristics.78 This interest is due to 
an increasing amount of evidence reporting the successful 
use of honey in the treatment of topical infections, some 
of which are not responsive to conventional treatments.46,79 
Several in vitro studies have reported that manuka honey has 
a synergistic activity when combined with antibiotics such 
as oxacillin,80 rifampicin,52 and vancomycin.55 In addition, 
honey can be used for prolonged treatments due to its low 
toxicity,35,81 and to date, little bacterial resistance to honey 
has been reported.82
Despite the apparent benefits of honey for the manage-
ment of infection, its use is not currently widespread in the 
developed world. The poor uptake by clinicians47 is due in 
part to a lack of scientific data pinpointing the mode of action 
against pathogens of interest.27 To combat these concerns, the 
past two decades have seen the number of research groups 
and the number of papers published on honey steadily rise, 
with studies focusing on the identification of active compo-
nents, mode of action, and clinical efficacy of honey. Herein, 
we review the current understanding of these aspects, with 
a focus on manuka honey due to its perceived enhanced 
antimicrobial activity (compared to other honey types), and 
Table 1 Summary of medical claims, both historical and modern, 
which have been attributed to honey
Timeframe Claim References
Historical wound salve (Roman, egyptian, Assyrian,  
Chinese, and Greek texts all reference  
the use of honey to treat wounds)
41,42
Treatment of gut diseases  
(diarrhea and constipation)
41
Pain relief 41
Control of acute fever 41
Treatment of eye infection 43
Modern Control of infection in wounds (including  
surgical, ulcerated, and burn wounds)
39,42,44–49
Treatment of multidrug-resistant  
topical infections
50–52
Treatment of bacterial biofilm infections 53–61
Treatment of bacterial gut infections  
(ie, Helicobacter pylori, Clostridium difficile)
56,62,63
Promotion of faster wound healing 64–66
wound debridement 67,68
Decreased duration of diarrhea and 
gastroenteritis
69,70
Conjunctivitis 44
Treatment of cancer 35,71
Alleviation of chemotherapy treatment 
symptoms
72–74
Decreased inflammation 75,76
Reduction of Crohn’s disease symptoms 77
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since it is already a licensed medical product in Australia, 
New Zealand, the UK, Europe, Canada, and US.83
Components of honey with antimicrobial 
activity
Defining the precise cause of the antimicrobial activity seen 
in honey is complicated due to the multifactorial nature of 
honey. Honeys have high osmolality due to the high concen-
tration of sugars,29 and it has been shown that 61% of honeys 
tested have antibacterial activity, which can be attributed 
solely to their high osmotic potential.30 In addition to this 
feature, the majority of non-manuka honeys’ antimicrobial 
activity is derived from the production of hydrogen peroxide 
(H
2
O
2
) upon dilution and subsequent generation of reactive 
oxygen species.84 Although the activity generated by H
2
O
2
 is 
potent, that activity can be curtailed by catalase.85 In a wound 
environment, where catalase is commonly released from 
human tissue, this curtailment leads to reduced antimicrobial 
activity of the honeys, therefore raising doubts over their 
use in a clinical setting. Other components such as immune 
modulatory molecules, eg, bee defensin 1,85 phenolics,86,87 
and flavonoid compounds,88 also contribute to activity in 
some honeys.
The antimicrobial activity of manuka honey is not H
2
O
2
-
based; thus far, however, the constituents responsible for its 
activity have not yet been fully elucidated.89 To date, both 
methylglyoxal (MGO) and leptosperin have been identified as 
major contributors to its enhanced antimicrobial activity.90,91 
An overview of the active components of a range of honeys, 
including manuka honey, coupled with their mechanism of 
action, is given in Table 2.
There are phenolic compounds within manuka honey 
that remain unidentified.89 Some of these compounds, such 
as leptosperin, could have activity similar to MGO.91 A study 
testing 20 Canadian honeys showed that those containing the 
highest quantity of phenolic compounds, in this case wild-
flower and buckwheat honeys, also had the most antioxidant 
and antimicrobial activity.97 Other studies have also shown 
Table 2 Brief description of the antibacterial compounds currently understood to be contained within honey and a description of their 
mechanism of action
Component Type of honey Antimicrobial effect References
Bee defensin 1 Revamil® An antimicrobial peptide produced and secreted by the  
bees into the honey. Bee defensin 1 has been isolated  
from non-manuka honey. The antimicrobial activity  
of bee defensin 1 is due to its ability to form pores  
in bacterial membranes, compromising membrane  
integrity and causing cell lysis.
85,92
Hydrogen peroxide (H2O2) Predominantly observed in  
non-manuka honeys (although  
low levels of activity are also  
found in manuka honey)
Generated by the activity of bee glucose oxidase, H2O2 is  
hypothesized to be a major antimicrobial component of  
many non-manuka honeys. Although the concentration  
of H2O2 within honey is far below that used medically, it  
is capable of causing DNA damage and interacting with  
other components of the honey, increasing its activity  
through hydroxyl radical production.
31,50
Leptosperin Manuka honey initially named leptosin, this molecule is a novel glycoside  
of methyl syringate, which inhibits myeloperoxidase  
activity. Leptosperin is only found in manuka honey, and  
so has been proposed as a biological marker for manuka  
honey. Concentrations of leptosperin are positively  
correlated with the antibacterial activity of manuka  
honey, although to date, no mechanism of action has  
been elucidated.
93,91
Jelleins Canadian buckwheat honey,  
and Canadian honey of a  
mixed source also containing  
buckwheat
Antimicrobial peptides contained in the major royal  
jelly precursor protein. Polypeptides with high affinity  
to jelleins have been shown to cause cell membrane  
damage in both Bacillus subtilis and Escherichia coli.
94
Methylglyoxal (MGO) Manuka honey MGO is found only in manuka honey, and concentrations  
increase as honey ripens. During maturation, MGO is  
converted from dihydroxyacetone via non-enzymatic  
Maillard-like reactions. The antimicrobial activity of MGO  
is derived from its ability to inactivate proteins by  
cross-linking them.
90,95,96
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that in honey where H
2
O
2
 activity is not present (due to the 
addition of exogenous catalase), residual antioxidant activity 
is still observed.85,98
The mechanism of action  
of methylglyoxal
As mentioned above, manuka honey has been shown to have 
a very high level of non-H
2
O
2
 antimicrobial activity when 
compared to other honeys. This high level of activity has been 
measured and researched, and the improved levels of anti-
bacterial efficacy have been attributed to several compounds 
isolated from manuka honey.85,87,99,100 The overall antibacterial 
activity of medical grade manuka honey is graded on one of 
two scales; MGO concentration within the honey, or unique 
manuka factor (UMF). The UMF rating is based on a linear 
relationship with phenol when tested against S. aureus.30 
MGO is a 1,2-dicarbonyl compound, which is not exclusive 
to manuka honey, and can be widely found in foodstuffs.90,100 
A study has demonstrated that MGO concentration within 
manuka honey is directly correlated to the UMF value,100 
indicating that it is responsible for the antimicrobial activity 
observed. MGO concentrations are much higher in manuka 
honey (between 38 and 725 mg/kg) than in other honey types 
(1.6 to 24 mg/kg).90
MGO can be formed both enzymatically and non-
 enzymatically, depending on the other components present 
in the honey and environmental conditions.101 MGO within 
manuka honey is primarily formed by the conversion of dihy-
droxyacetone to MGO by non-enzymatic  Maillard reactions.96 
Manuka honey collected from the hive often contains 
relatively low levels of MGO and a high concentration of 
dihydroxyacetone. During storage, this relationship inverts, 
and MGO levels within the honey increase, due to conversion 
of dihydroxyacetone.95
Antibacterial properties of manuka honey
Manuka honey is known to have antibacterial efficacy against 
a wide range pathogens, acting on both antibiotic-sensitive 
and antibiotic-resistant strains (Table 3).39,102,103
While MGO is deemed to produce the majority of manuka 
honey’s antibacterial activity, it is interesting to note that 
its neutralization has negligible effects on manuka honey’s 
ability to inhibit P. aeruginosa. This is in stark contrast to 
S. aureus and Bacillus subtilis, where the neutralization of 
MGO results in reduced activity.90,104 This result confirms 
the presence of other compounds with inhibitory efficacy, at 
least against P. aeruginosa. Due to the plethora of compounds 
within manuka honey, there will undoubtedly be a complex 
interplay between the various compounds. It is plausible that 
some interactions may lead to an additive/synergistic action 
not observed in the individual components. Therefore, the 
UMF rating appears to be the more thorough method of cal-
culating antibacterial efficacy, encompassing “all” activity 
and not that derived solely from MGO; however, this theory 
does have limitations: only the activity against the organism 
tested can truly be confirmed, as some compounds appear to 
have organism-specific activity. Therefore, single organism 
testing (against S. aureus, in this instance) can lead to spuri-
ous results. Furthermore, as manuka honey contains a range 
of compounds, their diffusion through the agar may vary, 
producing misleading results. It is clear that manuka honey 
has antibacterial efficacy, but how we evaluate this activity 
should be further investigated. A standardized method (such 
as micro broth dilution) against a panel of organisms should 
ensure all aspects of inhibitory efficacy are captured in a 
reproducible way.
It is important to note that although manuka honey is 
the only honey currently recognized as having bioactive 
concentrations of MGO, studies have shown that it may be 
possible to augment non-manuka honeys by adding MGO 
or its precursor dihydroxyacetone. One study showed that 
the addition of dihydroxyacetone to clover honey led to 
MGO detection.95 In addition, supplementation of honeys 
with MGO can increase bactericidal activity to a level com-
parable with manuka honey.105 Similarly, supplementation 
with antimicrobial peptides, such as BP2, increased the 
speed of bacterial inactivation by Revamil® honey when 
used against in vitro cultures of six antibiotic-resistant 
bacterial species.104
To the best of our knowledge, bacterial resistance to 
manuka honey has not been observed in a clinical setting; 
however, the emergence of cells with decreased suscepti-
bility to honey has been reported in vitro.106 However, the 
concentration of manuka honey tolerated was below that 
Table 3 Species of bacteria known to be inhibited by manuka 
honey
Achromobacter  
xylosoxidans
Enterococcus  
faecium
Pseudomonas 
aeruginosa
Acinetobacter  
baumannii
Haemophilus  
influenzae
Salmonella spp.
Burkholderia cepacia Helicobacter pylori Shigella spp.
Burkholderia  
cenocepacia
Klebsiella  
pneumoniae
Stenotrophomonas 
maltophilia
Campylobacter jejuni Listeria  
monocytogenes
Streptococcus pyogenes
Clostridium difficile Neisseria spp. Staphylococcus aureus
Escherichia coli Proteus spp. Yersinia spp.
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which would be achieved in clinical settings where undiluted 
manuka honey is used. Conversely, in studies investigat-
ing the purposeful passage of cells through sub-inhibitory 
concentrations of manuka honey did not result in a stable, 
resistant phenotype.82,103
Manuka honey has demonstrated eff icacy against 
a range of organisms assuming the biofilm phenotype 
in vitro,56,60,107–109 has been shown to inhibit bacterial species 
where individual strains have vastly different biofilm-forming 
abilities,59 and has been proved to inhibit bacteria where 
multi-species biofilms are present.54 A study using manuka-
type honeys suggests MGO requires other components 
(excluding sugars) to have full antibiofilm actions.59 This 
result reinforces the notion that multiple compounds in 
manuka honey produce inhibitory effects, some of which 
might enhance others. When assessing MGO solely, it is 
capable of inhibiting S. aureus and P. aeruginosa biofilms, 
suggesting some role in the inhibition of this phenotype.109
While the antibacterial qualities of manuka honey alone 
are extremely promising, combination therapy is now being 
thoroughly scrutinized as a way of reinvigorating antibiotics 
that are no longer effective.110–112 Researchers have shown that 
in vitro combination therapy using sub-inhibitory concen-
trations of manuka honey reduces the Minimum Inhibitory 
Concentration (MIC) of antibiotics, effectively “reversing” 
AMR.39,80 To date, improved antibacterial efficacy for colis-
tin, imipenem, mupirocin, rifampicin, and tetracycline has 
been demonstrated when combined with manuka honey.39,52 
These additive/synergistic actions have also been observed 
against bacteria assuming a biofilm phenotype.55 Additive 
effects against P. aeruginosa biofilms treated with gentamicin 
and manuka honey and synergism between manuka honey 
and vancomycin against S. aureus biofilms have also been 
reported.55 These combinations open up a new avenue for 
future antimicrobial development. Furthermore, with inhibi-
tory activity demonstrated against biofilms,9 the potential for 
manuka honey to be utilized clinically, inhibiting both acute 
and chronic infections, is highly promising.
Mechanisms of antibacterial action  
of manuka honey
The mechanism of action for manuka honey’s antibacterial 
activity has mainly been elucidated against two prominent 
opportunistic pathogens: S. aureus and P. aeruginosa. 
Interestingly, these mechanistic activities appear to differ 
greatly from one another. The first documented mechanistic 
activity for manuka honey was observed against S. aureus, 
where marked structural changes were observed in S. aureus 
cells treated with inhibitory concentrations.113
It was later confirmed that manuka honey causes disruption 
to the regular cell division process of S. aureus114 (Figure 1). 
Under optimal conditions, bacterial cells duplicate and seg-
regate their chromosome, forming a proteinaceous ring (the 
septum) across the midcell, creating two still-joined daughter 
cells.115 The completion of cell division occurs when pepti-
doglycan (murein) hydrolases degrade the cell wall between 
the two daughter cells, allowing separation.116 Manuka 
honey has been shown to inhibit the activity (and not the 
Regular cell function Cell division initiation Septa formation Septa completion Failure to separate
Septa formation begins
through the recruitment of
FtsZ at the midpoint of the
dividing cell. Forming a ring
structure, this protein
sequesters other cell division
proteins building up the
septa.
Septa formation is
completed, segregating the
two cells.
Peptidoglycan (murein)
hydrolases that are required to
degrade the septa structure
(resulting in cell separation),
are down-regulated through
the action of manuka honey,
causing cells to remain
attached and ultimately results
in cell death.
S. aureus cells prepare to
divide into two daughter cells.
Chromosome
separation
FtsZ
Septa
ring
forming
Septa
completion
Manuka honey
Cell death
Failure of the
septa to degrade
Reduced
murein
hydrolase
S. aureus cells duplicate the
genetic material in
preparation for cell division,
separating the
chromosomes to opposite
sides of the dividing cells.
Figure 1 The proposed mechanism by which manuka honey inhibits methicillin-resistant Staphylococcus aureus (MRSA). Manuka honey is thought to affect the latter stages 
of cell division, following the completion of the septa formation. The reduced production of murein (peptidoglycan) hydrolase and/or its sequestering into an inactive state 
results in the two daughter cells remaining attached due to the inability of the septa to be degraded, which ultimately leads to cell death.
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expression) of murein hydrolase, causing a build-up of septated 
non-dividing cells.114 Interestingly, many papers conclude 
the antibacterial action of manuka honey against S. aureus is 
bactericidal;85,104,113 however, the mechanism described points 
more toward bacteriostatic activity. Potentially, cells may be 
viable yet non-culturable. Several papers conclude that the 
effects seen are independent of the sugars within honey,113 
with one suggesting MGO is also not the causative agent of 
these inhibitory effects.114
In contrast to the mechanism observed in S. aureus, stud-
ies have proposed an entirely different mechanism against 
P. aeruginosa. P. aeruginosa cells can tolerate higher con-
centrations of manuka honey when compared to S. aureus, 
with inhibitory concentrations causing the loss of cellular 
integrity, leading to extensive cell lysis and cell death.117 
P. aeruginosa modulates its structural integrity through the 
production of a key anchor protein: outer membrane protein F 
(OprF).118 This protein provides a vital link between the outer 
membrane and underlying peptidoglycan layer, ensuring cell 
envelope homeostasis and regular cell shape.118,119 Reduced 
OprF expression has been observed in populations treated 
with manuka honey, and a concomitant increase in membrane 
blebbing and cell lysis has also been detected (Figure 2).120
The different mechanistic actions observed against 
P. aeruginosa (compared to S. aureus) highlights the potential 
for multiple modes of action, and multiple inhibitory com-
pounds in manuka honey. One noteworthy point is that the 
conserved nature of the cell division process among bacteria 
suggests manuka honey may affect the cell division process 
of P. aeruginosa. This effect was not observed in the studies 
above; however, the rate at which cell lysis occurs may not 
allow for such observations. Published work highlights 
the necessity of membrane potential for the correct spatial 
organization of cell division proteins and regular cell 
division function.121 This indicates an as yet unidentified 
link between the mechanistic effects observed in S. aureus 
and P. aeruginosa.
In other studies, exposure to manuka honey has been 
shown to have other effects against a range of organisms. 
Against P. aeruginosa, manuka honey suppresses the class I 
master regulators (FleQ and FliA), inhibiting the regulatory 
cascade required for flagellum production and leading to a 
significant reduction in flagellated cells.61 This observation 
is of clinical significance as adhesion and cellular motility 
are required for invasive virulence.122,123 Invasive virulence 
is problematic, as it allows the dissemination of cells 
through the bloodstream (bacteremia) to internal organs, 
which can prove fatal; therefore, the potential to reduce 
this process is highly valuable. The ability of P. aerugi-
nosa to sequester iron from a host may also be prohibited 
through manuka honey treatment, following the observation 
of reduced siderophore production in treated samples.124 
Sub-inhibitory concentrations are shown to inhibit cellular 
binding with fibronectin through the loss of two streptococ-
cal surface proteins, SoF and SfbI.107 In wound infections, 
high concentrations of fibronectin are observed;125 therefore, 
Regular cell function
Outer membrane protein F (OprF) is
protein that ensures regular cell shape
and envelope homeostasis with various
porin functions and is required for the
full virulence of P. aeruginosa.
When treated with manuka honey,
there is a significant reduction in the
expression of OprF. This leads to a
reduction in membrane stability and
blebbing of the outer membrane as it
dissociates from the underlying
peptidoglycan layer.
Instability in the outer membrane
makes the cell particularly susceptible
to osmotic stress. The high sugar
content and low water content of manuka
honey causes cell lysis to occur, even
when diluted.
Blebs burst via
osmotic shock
Membrane
blebbing
Membrane
blebbing
Outer membrane
protein (OprF)External environment
Outer membrane
Periplasm
Cytoplasm
Inner membrane
Peptidoglycan
Absence of OprF
N
C
Absent covalent cross links
Loss of cell function Irreversible cell damage
Figure 2 The proposed mechanism by which manuka honey inhibits Pseudomonas aeruginosa. Manuka honey is proposed to cause destabilization of the cell envelope through 
the down-regulation of a key structural protein (OprF), which is involved in maintaining cell shape and cell envelope stability. The loss of this protein results in membrane 
blebbing, which decreases cellular viability and ultimately leads to cell lysis.
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the inability of Streptococcus pyogenes to bind to the host 
may impact on its pathogenicity.
In addition to the studies into S. aureus, P. aeruginosa, and 
S. pyogenes, a study into the global action of manuka honey 
on Escherichia coli demonstrated that following exposure to 
manuka honey, 2% of the genes were up-regulated, while 1% 
were down-regulated by twofold or more.103 Up-regulation 
appears to occur across genes involved in stress response; 
those genes down-regulated are thought to encode products 
involved in protein synthesis.103 Conversely, down-regulation 
(16-fold) of a universal stress protein A (UspA) in S. aureus 
cells treated with honey was observed.126 Another study has 
shown large-scale down-regulation of critical virulence genes 
(enterotoxins, fibronectin-binding proteins, hemolysins, and 
lipases), with concomitant reductions in global regulators 
and quorum-sensing genes.51 These mechanistic effects, both 
lethal and non-lethal, are a testament to the inhibitory efficacy 
of manuka honey and confirm its broad spectrum of effects.
Applications of manuka honey  
as an antibacterial agent
Given the remarkable properties of manuka honey, it is unsur-
prising that there are now several licensed medical products 
based on manuka honey available, and it is worth noting that 
in addition to antimicrobial compounds, honey also contains 
compounds that enable it to modulate the activity of immune 
cells and promote rapid wound healing.46,65,67 However, 
despite the claims made, its use has mainly been restricted 
to use as an antibacterial agent in the treatment of infected 
burns and wounds.78,79
This limited uptake of honey in clinical practice could 
in part be due to a lack of high-quality evidence supporting 
its use clinically. Despite the large amount of in vitro work 
supporting its potential in vivo use, systematic reviews cov-
ering the use of honey in wound management have mostly 
stated that the evidence for clinical use is weak. However, 
when considering end-point measurements chosen (healing 
rather than antibacterial activity), inconsistent study design, 
varying honeys used, and diverse patient population, it is 
easy to see why it has been difficult to satisfactorily col-
late the data.48,127–131 A recent systematic review has given a 
positive view on the evidence supporting honey, suggesting 
that honey does lead to improved healing in a variety of 
wounds, including partial thickness burns, as well as acute 
and chronic wounds, when compared to silver sulfadiazine 
or sugar dressings.128 There is clearly still a need for larger 
scale, well-designed multicenter randomized clinical trials 
to improve the evidence base available.
Conclusion
AMR is one of the greatest medical challenges the world 
faces; it was estimated recently that by 2050, AMR will 
account for ten million extra deaths annually worldwide, with 
additional economic costs in the region of $100 trillion.132 
In order to combat this challenge, antimicrobial agents with 
a broad spectrum of activity are required. There is potential 
to use honey to target virulence rather than viability, thereby 
reducing the likelihood of resistance occurring and making 
it an interesting candidate for further investigation.
The ability of manuka to act synergistically with antibiot-
ics also opens up new possibilities for its use as a topical agent 
and possibly as part of a combined regimen. Such statements 
do raise immediate problems, however; one of the largest 
hurdles facing manuka honey’s introduction as a front-line 
product (and not last-resort, as is often the case) is the ability 
to reproduce the excellent efficacy observed in vitro during 
in vivo clinical trials. Additionally, the integration of manuka 
honey into mainstream wound care would ideally require the 
exact composition of honey to be fully investigated. This 
would allow assessment of the complex interplay compounds 
may have with one another, and may help clinicians deter-
mine whether honeys (manuka or otherwise) would be more 
effective against certain infection-causing species. Until the 
exact compounds causing inhibitory effects are identified and 
their interplay with other compounds investigated, the uptake 
of manuka honey in the clinical environment will remain 
inconsistent, possibly to the detriment of patients.
Disclosure
The authors report no conflict of interest in this work.
References
1. Pantosti A, Venditti M. What is MRSA? Eur Respir J. 2009;34(5): 
1190–1196.
2. Chen CH, Lin LC, Chang YJ, Chen YM, Chang CY, Huang CC. Infection 
control programs and antibiotic control programs to limit transmission 
of multi-drug resistant Acinetobacter baumannii infections: evolution of 
old problems and new challenges for institutes. Int J Environ Res Public 
Health. 2015;12(8):8871–8882.
3. Daniel DS, Lee SM, Dykes GA, Rahman S. Public health risks of multiple- 
drug-resistant Enterococcus spp. in Southeast Asia. 2015;81(18): 
6090–6097.
4. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance 
of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322–332.
5. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends 
in antimicrobial resistance among urinary tract infection isolates of 
Escherichia coli from female outpatients in the United States. Antimicrob 
Agents Chemother. 2002;46(8):2540–2545.
6. Thornton RB, Wiertsema SP, Kirkham LA, et al. Neutrophil extracel-
lular traps and bacterial biofilms in middle ear effusion of children with 
recurrent acute otitis media – a potential treatment target. PLoS One. 
2013;8(2):e53837.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 B
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
90
.1
27
.1
85
 o
n 
07
-S
ep
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Biology 2015:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
222
Roberts et al
 7. Thornton RB, Rigby PJ, Wiertsema SP, et al. Multi-species bacterial 
biofilm and intracellular infection in otitis media. BMC Pediatr. 
2011;11:94.
 8. Anvarinejad M, Japoni A, Rafaatpour N, et al. Burn patients infected 
with metallo-beta-lactamase-producing Pseudomonas aeruginosa: 
multidrug-resistant strains. Arch Trauma Res. 2014;3(2):e18182.
 9. Philips PL. Yang QDS, Sampson EM, Azeke A, Schultz GS. Antimicrobial 
dressing efficacy against mature Pseudomonas aeruginosa biofilm on 
procine skin explants. Int Wound J. 2015;12(4):469–483.
 10. Huttner A, Harbarth S, Carlet J, et al. Antimicrobial resistance: a global 
view from the 2013 World Healthcare-Associated Infections Forum. 
Antimicrob Resist Infect Control. 2013;2:31.
 11. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science. 
August 28, 2009;325(5944):1089–1093.
 12. Bragginton EC, Piddock LJ. UK and European Union public and 
 charitable funding from 2008 to 2013 for bacteriology and antibiotic 
research in the UK: an observational study. Lancet Infect Dis. 2014;14(9): 
857–868.
 13. Römling U, Kjelleberg S, Normark S, Nyman L, Uhlin BE, Åkerlund B. 
Microbial biofilm formation: a need to act. J Intern Med. 2014;276(2): 
98–110.
 14. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of 
antimicrobial-resistant infections in a Chicago teaching hospital: implica-
tions for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–1184.
 15. Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 
2013;346:f1493.
 16. Allen HK, Trachsel J, Looft T, Casey TA. Finding alternatives to 
antibiotics. Ann N Y Acad Sci. 2014;1323(1):91–100.
 17. Prabhu S, Poulose E. Silver nanoparticles: mechanism of antimicrobial 
action, synthesis, medical applications, and toxicity effects. Int Nano 
Lett. 2012;2(1):1–10.
 18. Hyldgaard M, Mygind T, Meyer RL. Essential oils in food preservation: 
mode of action, synergies, and interactions with food matrix components. 
Front Microbiol. 2012;3:12.
 19. Viuda-Martos M, Ruiz-Navajas Y, Fernández-López J, Pérez-Álvarez JA. 
Functional properties of honey, propolis, and royal jelly. J Food Sci. 
2008;73(9):R117–R124.
 20. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. 
Antimicrob Agents Chemother. 2001;45(3):649–659.
 21. Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K. 
Antimicrobial activity of the metals and metal oxide nanoparticles. 
Mater Sci Eng C Mater Biol Appl. 2014;44:278–284.
 22. Hraiech S, Brégeon F, Rolain JM. Bacteriophage-based therapy in cystic 
fibrosis-associated Pseudomonas aeruginosa infections: rationale and 
current status. Drug Des Devel Ther. 2015;9:3653–3663.
 23. Maddocks SE, Jenkins RE, Rowlands RS, Purdy KJ, Cooper RA. 
Manuka honey inhibits adhesion and invasion of medically important 
wound bacteria in vitro. Future Microbiol. 2013;8(12):1523–1536.
 24. Merckoll P, Jonassen TØ, Vad ME, Jeansson SL, Melby KK. Bacteria, 
biofilm and honey: a study of the effects of honey on ‘planktonic’ 
and biofilm-embedded chronic wound bacteria. Scand J Infect Dis. 
2009;41(5):341–347.
 25. Alvarez-Suarez J, Tulipani S, Romandini S, Bertoli E, Battino M. 
Contribution of honey in nutrition and human health: a review. Med J 
Nutrition Metab. 2010;3(1):15–23.
 26. Ruiz-Argueso T, Rodriguez-Navarro A. Microbiology of ripening 
honey. Appl Microbiol. 1975;30(6):893–896.
 27. Eteraf-Oskouei T, Najafi M. Traditional and modern uses of natural 
honey in human diseases: a review. Iran J Basic Med Sci. 2013;16(6): 
731–742.
 28. Alvarez-Suarez JM, Giampieri F, Battino M. Honey as a source 
of dietary antioxidants: structures, bioavailability and evidence of 
protective effects against human chronic diseases. Curr Med Chem. 
2013;20(5):621–638.
 29. Alvarez-Suarez JM, Gasparrini M, Forbes-Hernández TY, Mazzoni L, 
Giampieri F. The composition and biological activity of honey: a focus 
on manuka honey. Foods. 2014;3(3):420–432.
 30. Allen KL, Molan PC, Reid GM. A survey of the antibacterial activity of 
some New Zealand honeys. J Pharm Pharmacol. 1991;43(12): 817–822.
 31. Brudzynski K, Abubaker K, St-Martin L, Castle A. Re-examining the 
role of hydrogen peroxide in bacteriostatic and bactericidal activities 
of honey. Front Microbiol. 2011;2:213.
 32. Tonks AJ, Cooper RA, Jones KP, Blair S, Parton J, Tonks A. Honey 
stimulates inflammatory cytokine production from monocytes. Cytokine. 
2003;21(5):242–247.
 33. Erejuwa OO, Sulaiman SA, Wahab MS, Sirajudeen KN, Salleh MS, 
Gurtu S. Glibenclamide or metformin combined with honey improves 
glycemic control in streptozotocin-induced diabetic rats. Int J Biol Sci. 
2011;7(2):244–252.
 34. Al-Waili NS. Natural honey lowers plasma glucose, C-reactive protein, 
homocysteine, and blood lipids in healthy, diabetic, and hyperlipidemic 
subjects: comparison with dextrose and sucrose. J Med Food. 2004;7(1): 
100–107.
 35. Fernandez-Cabezudo MJ, El-Kharrag R, Torab F, et al. Intravenous 
Administration of Manuka Honey Inhibits Tumor Growth and Improves 
Host Survival When Used in Combination with Chemotherapy in a 
Melanoma Mouse Model. PLoS One. 2013;8(2):e55993.
 36. Irish J, Carter DA, Shokohi T, Blair SE. Honey has an antifungal effect 
against Candida species. Med Mycol. 2006;44(3):289–291.
 37. Watanabe K, Rahmasari R, Matsunaga A, Haruyama T, Kobayashi N. 
Anti-influenza viral effects of honey in vitro: potent high activity of 
manuka honey. Arch Med Res. 2014;45(5):359–365.
 38. Cooper R, Jenkins L, Hooper S. Inhibition of biofilms of Pseudomonas 
aeruginosa by Medihoney in vitro. J Wound Care. 2014;23(3):93–96, 
98–100, 102 passim.
 39. Jenkins R, Cooper R. Improving antibiotic activity against wound 
pathogens with manuka honey in vitro. PLoS One. 2012;7(9):e45600.
 40. Maddocks SE, Jenkins RE. Honey: a sweet solution to the growing problem 
of antimicrobial resistance? Future Microbiol. 2013;8(11):1419–1429.
 41. Zumla A, Lulat A. Honey – a remedy rediscovered. J R Soc Med. 1989; 
82(7):384–385.
 42. Cooper R. The modern use of honey in the treatment of wounds. Bee 
World. 2005;86(4):110–113.
 43. Salehi A, Jabarzare S, Neurmohamadi M, Kheiri S, Rafieian-Kopaei M. 
A double blind clinical trial on the efficacy of honey drop in vernal 
keratoconjunctivitis. Evid Based Complement Alternat Med. 2014;2014: 
287540.
 44. Al-Waili NS. Investigating the antimicrobial activity of natural honey 
and its effects on the pathogenic bacterial infections of surgical wounds 
and conjunctiva. J Med Food. 2004;7(2):210–222.
 45. Chang EH, Alandejani T, Akbari E, Ostry A, Javer A. Double-blinded, 
randomized, controlled trial of medicated versus nonmedicated merocel 
sponges for functional endoscopic sinus surgery. J Otolaryngol Head 
Neck Surg. 2011;40(Suppl 1):S14–S19.
 46. Efem SE. Clinical observations on the wound healing properties of 
honey. Br J Surg. 1988;75(7):679–681.
 47. Molan PC. The evidence supporting the use of honey as a wound 
dressing. Int J Low Extrem Wounds. 2006;5(1):40–54.
 48. Moore OA, Smith LA, Campbell F, Seers K, McQuay HJ, Moore RA. 
Systematic review of the use of honey as a wound dressing. BMC 
Complement Altern Med. 2001;1:2.
 49. Phillips PL, Yang Q, Davis S, et al. Antimicrobial dressing efficacy 
against mature Pseudomonas aeruginosa biofilm on porcine skin 
explants. Int Wound J. 2015;12(4):469–483.
 50. Brudzynski K, Lannigan R. Mechanism of honey bacteriostatic action 
against MRSA and VRE involves hydroxyl radicals generated from 
honey’s hydrogen peroxide. Front Microbiol. 2012;3:36.
 51. Jenkins R, Burton N, Cooper R. Proteomic and genomic analysis 
of methicillin-resistant Staphylococcus aureus (MRSA) exposed to 
manuka honey in vitro demonstrated down-regulation of virulence 
markers. J Antimicrob Chemother. 2014;69(3):603–615.
 52. Müller P, Alber DG, Turnbull L, et al. Synergism between Medihoney 
and rifampicin against methicillin-resistant Staphylococcus aureus 
(MRSA). PLoS One. 2013;8(2):e57679.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 B
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
90
.1
27
.1
85
 o
n 
07
-S
ep
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Biology 2015:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
223
Antibacterial manuka honey
 53. Ansari MJ, Al-Ghamdi A, Usmani S, et al. Effect of jujube honey 
on Candida albicans growth and biofilm formation. Arch Med Res. 
2013;44(5):352–360.
 54. Badet C, Quero F. The in vitro effect of manuka honeys on growth and 
adherence of oral bacteria. Anaerobe. 2011;17(1):19–22.
 55. Campeau ME, Patel R. Antibiofilm activity of Manuka honey in com-
bination with antibiotics. Int J Bacteriol. 2014;2014:1–7.
 56. Hammond EN, Donkor ES, Brown CA. Biofilm formation of Clostrid-
ium difficile and susceptibility to Manuka honey. BMC Complement 
Altern Med. 2014;14:329.
 57. Lee JH, Park JH, Kim JA, et al. Low concentrations of honey reduce 
biofilm formation, quorum sensing, and virulence in Escherichia coli 
O157:H7. Biofouling. 2011;27(10):1095–1104.
 58. Lerrer B, Zinger-Yosovich KD, Avrahami B, Gilboa-Garber N. 
Honey and royal jelly, like human milk, abrogate lectin-dependent 
infection-preceding Pseudomonas aeruginosa adhesion. ISME J. 
2007;1(2):149–155.
 59. Lu J, Turnbull L, Burke CM, et al. Manuka-type honeys can eradicate 
biofilms produced by Staphylococcus aureus strains with different 
biofilm-forming abilities. PeerJ. 2014;2:e326.
 60. Majtan J, Bohova J, Horniackova M, Klaudiny J, Majtan V. Anti-biofilm 
effects of honey against wound pathogens Proteus mirabilis and Enter-
obacter cloacae. Phytother Res. 2014;28(1):69–75.
 61. Roberts AE, Maddocks SE, Cooper RA. Manuka honey reduces 
the motility of Pseudomonas aeruginosa by suppression of flagella-
associated genes. J Antimicrob Chemother. 2015;70(3):716–725.
 62. Matongo F, Nwodo UU. In vitro assessment of Helicobacter pylori 
ureases inhibition by honey fractions. Arch Med Res. 2014;45(7): 
540–546.
 63. Manyi-Loh CE, Clarke AM, Munzhelele T, Green E, Mkwetshana NF, 
Ndip RN. Selected South African honeys and their extracts pos-
sess in vitro anti-Helicobacter pylori activity. Arch Med Res. 
2010;41(5):324–331.
 64. Witman CE, Downs BW. Topical honey for scalp defects: an alterna-
tive to surgical scalp reconstruction. Plast Reconstr Surg Glob Open. 
2015;3(5):e393.
 65. Ker-Woon C, Abd Ghafar N, Hui CK, Mohd Yusof YA, Wan Ngah WZ. 
The effects of acacia honey on in vitro corneal abrasion wound healing 
model. BMC Cell Biol. 2015;16:2.
 66. Mohamed H, Salma MA, Al Lenjawi B, et al. The efficacy and safety 
of natural honey on the healing of foot ulcers: a case series. Wounds. 
2015;27(4):103–114.
 67. Gray C, Ishii F. Using active Leptospermum honey in the debride-
ment process: 6 challenging cases from the inner city. Ostomy Wound 
Manage. 2015;61(4):63–66.
 68. Amaya R. Safety and eff icacy of active Leptospermum honey 
in neonatal and paediatric wound debridement. J Wound Care. 
2015;24(3):95;97–103.
 69. Haffejee IE, Moosa A. Honey in the treatment of infantile gastroenteritis. 
Br Med J (Clin Res Ed). 1985;290(6485):1866–1867.
 70. Abdulrhman MA, Mekawy MA, Awadalla MM, Mohamed AH. 
Bee honey added to the oral rehydration solution in treatment of 
gastroenteritis in infants and children. J Med Food. 2010;13(3): 
605–609.
 71. Sadeghi-Aliabadi H, Hamzeh J, Mirian M. Investigation of Astragalus 
honey and propolis extract’s cytotoxic effect on two human cancer cell 
lines and their oncogen and proapoptotic gene expression profiles. Adv 
Biomed Res. 2015;4:42.
 72. Cho HK, Jeong YM, Lee HS, Lee YJ, Hwang SH. Effects of honey on 
oral mucositis in patients with head and neck cancer: a meta-analysis. 
Laryngoscope. 2015;125(9):2085–2092.
 73. Munstedt K, Voss B, Kullmer U, Schneider U, Hübner J. Bee pollen and 
honey for the alleviation of hot flushes and other menopausal symptoms 
in breast cancer patients. Mol Clin Oncol. 2015;3(4):869–874.
 74. Hamad R, Jayakumar C, Ranganathan P, et al. Honey feeding protects 
kidney against cisplatin nephrotoxicity through suppression of 
inflammation. Clin Exp Pharmacol Physiol. 2015;42(8):843–848.
 75. Kamaruzaman NA, Sulaiman SA, Kaur G, Yahaya B. Inhalation of 
honey reduces airway inflammation and histopathological changes in a 
rabbit model of ovalbumin-induced chronic asthma. BMC Complement 
Altern Med. 2014;14:176.
 76. Borsato DM, Prudente AS, Döll-Boscardin PM, et al. Topical anti-
inflammatory activity of a monofloral honey of Mimosa scabrella 
provided by Melipona marginata during winter in southern Brazil. 
J Med Food. 2014;17(7):817–825.
 77. Octoratou M, Merikas E, Malgarinos G, Stanciu C, Triantafillidis JK. 
A prospective study of pre-illness diet in newly diagnosed 
patients with Crohn’s disease. Rev Med Chir Soc Med Nat lasi. 
2012;116(1):40–49.
 78. Kwakman PHS, Van den Akker JPC, Güçlü A, et al. Medical-grade 
honey kills antibiotic-resistant bacteria in vitro and eradicates skin 
colonization. Clin Infect Dis. 2008;46(11):1677–1682.
 79. Visavadia BG, Honeysett J, Danford MH. Manuka honey dressing: an 
effective treatment for chronic wound infections. Br J Oral Maxillofac 
Surg. 2008;46(1):55–56.
 80. Jenkins RE, Cooper R. Synergy between oxacillin and manuka honey 
sensitizes methicillin-resistant Staphylococcus aureus to oxacillin. 
Journal of Antimicrobial Chemotherapy. 2012;67(6):1405–1407.
 81. Medhi B, Prakash A, Avti PK, Saikia UN, Pandhi P, Khanduja KL. 
Effect of manuka honey and sulfasalazine in combination to promote 
antioxidant defense system in experimentally induced ulcerative colitis 
model in rats. Indian J Exp Biol. 2008;46(8):583–590.
 82. Cooper RA, Jenkins L, Henriques AF, Duggan RS, Burton NF. Absence 
of bacterial resistance to medical-grade manuka honey. Eur J Clin 
Microbiol Infect Dis. 2010;29(10):1237–1241.
 83. Cooper R, Jenkins R. Are there feasible prospects for manuka honey 
as an alternative to conventional antimicrobials? Expert Rev Anti Infect 
Ther. 2012;10(6):623–625.
 84. Bang LM Buntting C, Molan P. The effect of dilution on the rate of 
hydrogen peroxide production in honey and its implications for wound 
healing. J Altern Complement Med. 2004;9(2):267–273.
 85. Kwakman PH, te Velde AA, de Boer L, Speijer D, Vandenbroucke-
Grauls CM, Zaat SA. How honey kills bacteria. FASEB J. 2010;24(7): 
2576–2582.
 86. Daher S, Gülaçar FO. Identification of new aromatic compounds in the 
New Zealand manuka honey by gas chromatography-mass spectrometry. 
J Chem. 2010;7(S1):S7–S14.
 87. Weston RJ, Mitchell KR, Allen KL. Antibacterial phenolic components 
of New Zealand manuka honey. Food Chem. 1999;64(3):295–301.
 88. Blasa M, Candiracci M, Accorsi A, Piacentini MP, Piatti E. Honey 
flavonoids as protection agents against oxidative damage to human red 
blood cells. Food Chem. 2007;104(4):1635–1640.
 89. Oelschlaegel S, Gruner M, Wang PN, Boettcher A, Koelling-Speer I, 
Speer K. Classification and Characterization of Manuka Honeys Based 
on Phenolic Compounds and Methylglyoxal. J Agric Food Chem. 
2012;60(29):7229–7237.
 90. Adams CJ, Boult CH, Deadman BJ, et al. Isolation by HPLC and charac-
terisation of the bioactive fraction of New Zealand manuka (Leptosper-
mum scoparium) honey. Carbohydr Res. 2008;343(4):651–659.
 91. Kato Y, Fujinaka R, Ishisaka A, Nitta Y, Kitamoto N, Takimoto Y. 
Plausible authentication of manuka honey and related products by 
measuring leptosperin with methyl syringate. J Agric Food Chem. 
2014;62(27):6400–6407.
 92. Klaudiny J, Albert S, Bachanová K, Kopernický J, Simúth J. Two 
structurally different defensin genes, one of them encoding a novel 
defensin isoform, are expressed in honeybee Apis mellifera. Insect 
Biochem Mol Biol. 2005;35(1):11–22.
 93. Kato Y, Umeda N, Maeda A, Matsumoto D, Kitamoto N, Kikuzaki H. 
Identification of a novel glycoside, leptosin, as a chemical marker of 
manuka honey. J Agric Food Chem. 2012;60(13):3418–3423.
 94. Brudzynski K, Sjaarda C. Honey glycoproteins containing antimicro-
bial peptides, jelleins of the major royal jelly protein 1, are responsible 
for the cell wall lytic and bactericidal activities of honey. PLoS One. 
2015;10(4):e0120238.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 B
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
90
.1
27
.1
85
 o
n 
07
-S
ep
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Biology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/research-and-reports-in-biology-journal
Research and Reports in Biology is an international, peer-reviewed, 
open access journal publishing original research, reports, editorials, 
reviews and commentaries on all areas of biology including ani-
mal biology, biochemical biology, cell biology, ecological studies, 
evolutionary biology, molecular biology, plant science and botany. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Research and Reports in Biology 2015:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
224
Roberts et al
 95. Adams CJ, Manley-Harris M, Molan PC. The origin of methylglyoxal 
in New Zealand manuka (Leptospermum scoparium) honey. Carbo-
hydrate Res. 2009;344(8):1050–1053.
 96. Weigel KU, Opitz T, Henle T. Studies on the occurrence and formation of 
1,2-dicarbonyls in honey. Eur Food Res Technol. 2004;218(2):147–151.
 97. Brudzynski K, Miotto D. The relationship between the content of 
Maillard reaction-like products and bioactivity of Canadian honeys. 
Food Chem. 2011;124(3):869–874.
 98. Irish J, Blair S, Carter DA. The antibacterial activity of honey derived 
from Australian flora. PLoS One. 2011;6(3):e18229.
 99. Lu J, Carter DA, Turnbull L, et al. The effect of New Zealand 
kanuka, manuka and clover honeys on bacterial growth dynamics 
and cellular morphology varies according to the species. PLoS One. 
2013;8(2):e55898.
 100. Mavric E, Wittmann S, Barth G, Henle T. Identification and quantifi-
cation of methylglyoxal as the dominant antibacterial constituent of 
Manuka (Leptospermum scoparium) honeys from New Zealand. Mol 
Nutr Food Res. 2008;52(4):483–489.
 101. Nemet I, Varga-Defterdarović L, Turk Z. Methylglyoxal in food and 
living organisms. Mol Nutr Food Res. 2006;50(12):1105–1117.
 102. Cooper RA, Molan PC, Harding KG. The sensitivity to honey of 
Gram-positive cocci of clinical significance isolated from wounds. 
J Appl Microbiol. 2002;93(5):857–863.
 103. Blair SE, Cokcetin NN, Harry EJ, Carter DA. The unusual antibacterial 
activity of medical-grade Leptospermum honey: antibacterial 
spectrum, resistance and transcriptome analysis. Eur J Clin Microbiol 
Infect Dis. 2009;28(10):1199–1208.
 104. Kwakman PH, de Boer L, Ruyter-Spira CP, et al. Medical-grade 
honey enriched with antimicrobial peptides has enhanced activity 
against antibiotic-resistant pathogens. Eur J Clin Microbiol Infect 
Dis. 2011;30(2):251–257.
 105. Jervis-Bardy J, Foreman A, Bray S, Tan L, Wormald PJ. Methylglyoxal-
infused honey mimics the anti-Staphylococcus aureus biofilm activity 
of manuka honey: potential implication in chronic rhinosinusitis. 
Laryngoscope. 2011;121(5):1104–1107.
 106. Camplin AL, Maddocks SE. Manuka honey treatment of biofilms 
of Pseudomonas aeruginosa results in the emergence of isolates 
with increased honey resistance. Ann Clin Microbiol Antimicrob. 
2014;13:19.
 107. Maddocks SE, Lopez MS, Rowlands RS, Cooper RA. Manuka 
honey inhibits the development of Streptococcus pyogenes biofilms 
and causes reduced expression of two fibronectin binding proteins. 
Microbiology. 2012;158(Pt 3):781–790.
 108. Alandejani T, Marsan J, Ferris W, Slinger R, Chan F. Effectiveness 
of honey on Staphylococcus aureus and Pseudomonas aeruginosa 
biofilms. Otolaryngol Head Neck Surg. Jul 2009;141(1):114–118.
 109. Kilty SJ, Duval M, Chan FT, Ferris W, Slinger R. Methylglyoxal: 
(active agent of manuka honey) in vitro activity against bacterial 
biofilms. Int Forum Allergy Rhinol. 2011;1(5):348–350.
 110. Fischbach MA. Combination therapies for combating antimicrobial 
resistance. Curr Opin Microbiol. 2011;14(5):519–523.
 111. Rahal JJ. Novel antibiotic combinations against infections with almost 
completely resistant Pseudomonas aeruginosa and Acinetobacter 
species. Clin Infect Dis. 2006;43(Suppl 2):S95–S99.
 112. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for 
treatment of infections with gram-negative bacteria. Clin Microbiol 
Rev. 2012;25(3):450–470.
 113. Henriques AF, Jenkins RE, Burton NF, Cooper RA. The intracellular 
effects of manuka honey on Staphylococcus aureus. Eur J Clin 
Microbiol Infect Dis. 2010;29(1):45–50.
 114. Jenkins R, Burton N, Cooper R. Manuka honey inhibits cell division in 
methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 
2011;66(11):2536–2542.
 115. Amick JD, Brun YV. Anatomy of a bacterial cell cycle. Genome Biol. 
2001;2(7):REVIEWS1020.
 116. Priyadarshini R, de Pedro MA, Young KD. Role of peptidoglycan 
amidases in the development and morphology of the division septum 
in Escherichia coli. J Bacteriol. 2007;189(14):5334–5347.
 117. Henriques AF, Jenkins RE, Burton NF, Cooper RA. The effect of 
manuka honey on the structure of Pseudomonas aeruginosa. Eur J 
Clin Microbiol Infect Dis. Feb 2011;30(2):167–171.
 118. Gotoh N, Wakebe H, Yoshihara E, Nakae T, Nishino T. Role of protein 
F in maintaining structural integrity of the Pseudomonas aeruginosa 
outer membrane. J Bacteriol. 1989;171(2):983–990.
 119. Sugawara E, Steiert M, Rouhani S, Nikaido H. Secondary structure 
of the outer membrane proteins OmpA of Escherichia coli and OprF 
of Pseudomonas aeruginosa. J Bacteriol. 1996;178(20):6067–6069.
 120. Roberts AE, Maddocks SE, Cooper RA. Manuka honey is bactericidal 
against Pseudomonas aeruginosa and results in differential expression 
of oprF and algD. Microbiology. 2012;158(Pt 12):3005–3013.
 121. Strahl H, Hamoen LW. Membrane potential is important for bacterial cell 
division. Proc Natl Acad Sci U S A. 2010;107(27):12281–12286.
 122. Drake D, Montie TC. Flagella, motility and invasive virulence of 
Pseudomonas aeruginosa. J Gen Microbiol. 1988;134(1):43–52.
 123. Haiko J, Westerlund-Wikström B. The role of the bacterial flagellum 
in adhesion and virulence. Biology (Basel). 2013;2(4):1242–1267.
 124. Kronda JM, Cooper RA, Maddocks SE. Manuka honey inhibits 
siderophore production in Pseudomonas aeruginosa. J Appl Microbiol. 
2013;115(1):86–90.
 125. To WS, Midwood KS. Plasma and cellular fibronectin: distinct and 
independent functions during tissue repair. Fibrogenesis Tissue Repair. 
2011;4:21.
 126. Jenkins R, Burton N, Cooper R. Effect of manuka honey on the expression 
of universal stress protein A in meticillin-resistant Staphylococcus 
aureus. Int J Antimicrob Agents. 2011;37(4):373–376.
 127. Jull AB, Rodgers A, Walker N. Honey as a topical treatment for 
wounds [review]. Cochrane Database Syst Rev. 2008;4:CD005083.
 128. Jull AB, Cullum N, Dumville JC, Westby MJ, Deshpande S, Walker N. 
Honey as a topical treatment for wounds [review]. Cochrane Database 
Syst Rev. 2015;3:CD005083.
 129. Bardy J, Slevin NJ, Mais KL, Molassiotis A. A systematic review of 
honey uses and its potential value within oncology care. J Clin Nurs. 
2008;17(19):2604–2623.
 130. Vandamme L, Heyneman A, Hoeksema H, Verbelen J, Monstrey S. 
Honey in modern wound care: a systematic review. Burns. 2013;39(8): 
1514–1525.
 131. Brölmann FE, Ubbink DT, Nelson EA, Munte K, van der Horst CM, 
Vermeulen H. Evidence-based decisions for local and systemic wound 
care. Br J Surg. 2012;99(9):1172–1183.
 132. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and 
wealth of nations. Rev Antimicrob Resist (Lond). 2014:1–22.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 B
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
90
.1
27
.1
85
 o
n 
07
-S
ep
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
